ALL-CAUSE TREATMENT DISCONTINUATION FOR OLANZAPINE COMPARED TO OTHER ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA: A META-ANALYSIS

被引：0
|
作者：
Soares-Weiser, K. [1 ]
Bechard-Evans, L. [1 ]
Lawson, A. H. [2 ]
Davis, J. [3 ]
Ascher-Svanum, H. [2 ]
机构：
[1] Enhance Reviews Ltd, London, England
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] Univ Illinois, Chicago, IL USA
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)72510-9
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A106 / A106
页数：1
相关论文
共 50 条
  • [1] Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis
    Soares-Weiser, Karla
    Bechard-Evans, Laura
    Lawson, Anthony Howard
    Davis, John
    Ascher-Svanum, Haya
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 (02) : 118 - 125
  • [2] All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics - An integrated analysis
    Beasley, Charles M., Jr.
    Stauffer, Virginia L.
    Liu-Seifert, Hong
    Taylor, Cindy C.
    Dunayevich, Eduardo
    Davis, John M.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2007, 27 (03) : 252 - 258
  • [3] All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotic agents: An integrated analysis
    Stauffer, VL
    Beasley, CM
    Liu-Seifert, H
    Taylor, CC
    Dunayevich, E
    Davis, JM
    SCHIZOPHRENIA RESEARCH, 2006, 81 : 68 - 69
  • [4] Number needed to treat (NNT) for all-cause medication discontinuation from randomized controlled trials comparing olanzapine to other antipsychotics for the treatment of schizophrenia
    Stauffer, Virginia
    Karagianis, Jamie
    Sutton, Virginia
    Ascher-Svanum, Haya
    Treuer, Tamas
    Silva de Lima, Mauricio
    Poole-Hoffmann, Vicki
    Tohen, Mauricio
    BIOLOGICAL PSYCHIATRY, 2007, 61 (08) : 259S - 259S
  • [5] Time to all-cause discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
    Swartz, M
    Zhu, B
    Ascher-Svanum, H
    Faries, D
    Tunis, S
    Landbloom, R
    Swanson, J
    SCHIZOPHRENIA BULLETIN, 2005, 31 (02) : 551 - 552
  • [6] Time to all-cause discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
    Swartz, MS
    Ascher-Svanum, H
    Faries, DE
    Tunis, SL
    Landbloom, R
    Swanson, J
    BIOLOGICAL PSYCHIATRY, 2005, 57 (08) : 44S - 44S
  • [7] All-Cause Treatment Discontinuation and Other Effectiveness Measures
    McEvoy, Joseph P.
    CNS SPECTRUMS, 2006, : 6 - 7
  • [8] Olanzapine versus other antipsychotics in the treatment of schizophrenia
    Masand, PS
    JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (10) : 828 - 828
  • [9] Treatment of the symptoms of schizophrenia: A meta-analysis comparing risperidone with other antipsychotics
    Lemmens, P
    Van Baelen, B
    Brecher, M
    SCHIZOPHRENIA RESEARCH, 1998, 29 (1-2) : 146 - 146
  • [10] Time to all-cause discontinuation following randomization to open-label olanzapine, risperidone, or conventional antipsychotic treatment for schizophrenia
    Ascher-Svanum, H
    Nyhuis, AW
    Tunis, SL
    Stevens, M
    BIOLOGICAL PSYCHIATRY, 2005, 57 (08) : 44S - 44S
12345